Our top pick for
Summit Therapeutics Inc is a biotechnology business based in the US. Summit Therapeutics shares (SMMT) are listed on the NASDAQ and all prices are listed in US Dollars. Summit Therapeutics employs 70 staff and has a trailing 12-month revenue of around USD$22.1 million.
|52-week range||USD$1.42 - USD$10.99|
|50-day moving average||USD$7.0071|
|200-day moving average||USD$4.7858|
|Wall St. target price||USD$4.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.225|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Summit Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Summit Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Summit Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Summit Therapeutics shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$22.1 million|
|Gross profit TTM||USD$17.2 million|
|Return on assets TTM||-36.13%|
|Return on equity TTM||0%|
|Market capitalisation||USD$500.4 million|
TTM: trailing 12 months
There are currently 289,991 Summit Therapeutics shares held short by investors – that's known as Summit Therapeutics's "short interest". This figure is 26.1% down from 392,538 last month.
There are a few different ways that this level of interest in shorting Summit Therapeutics shares can be evaluated.
Summit Therapeutics's "short interest ratio" (SIR) is the quantity of Summit Therapeutics shares currently shorted divided by the average quantity of Summit Therapeutics shares traded daily (recently around 295909.18367347). Summit Therapeutics's SIR currently stands at 0.98. In other words for every 100,000 Summit Therapeutics shares traded daily on the market, roughly 980 shares are currently held short.
However Summit Therapeutics's short interest can also be evaluated against the total number of Summit Therapeutics shares, or, against the total number of tradable Summit Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Summit Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Summit Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0072% of the tradable shares (for every 100,000 tradable Summit Therapeutics shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Summit Therapeutics.
Find out more about how you can short Summit Therapeutics stock.
We're not expecting Summit Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Summit Therapeutics's shares have ranged in value from as little as $1.42 up to $10.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Summit Therapeutics's is 0.6259. This would suggest that Summit Therapeutics's shares are less volatile than average (for this exchange).
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.